-

Baxter Announces Updates to Its Board of Directors

  • Addition of Stephen H. Rusckowski complements and expands current board expertise with deep healthcare industry and public company board experience
  • Michael Mahoney to resign after nearly eight years of board service

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed Stephen (Steve) H. Rusckowski, former chairman, president and chief executive officer of Quest Diagnostics, Inc., to its board of directors. Effective today, Mr. Rusckowski serves on Baxter’s Compensation and Human Capital, and Quality, Compliance and Technology Committees. In addition, the company has announced that Michael (Mike) Mahoney will be resigning from the board effective Sept. 13, 2023, following nearly eight years of service.

“We are pleased to welcome Steve to Baxter’s board,” said José (Joe) E. Almeida, chairman, president and chief executive officer. “His exemplary operational expertise, track record as a transformational leader, and distinguished career as a strategic operational executive will enhance our current board membership. I’m confident Steve’s patient-centric approach will further advance our Mission to Save and Sustain Lives.”

Added Almeida, “I also want to thank Mike for his many contributions to the Baxter board over his eight-year tenure. His extensive insight into the medical device industry and deep leadership experience have helped guide Baxter’s ongoing transformation, including our current strategic actions to drive greater growth, innovation and performance.”

About Steve Rusckowski

Mr. Rusckowski most recently served as chairman, president and chief executive officer of Quest Diagnostics, Inc. Prior to joining Quest Diagnostics, he was CEO of Philips Healthcare, and earlier in his career held roles of increasing responsibility at Hewlett-Packard Company and Procter & Gamble Company. Mr. Rusckowski currently serves as a director of Tenet Healthcare Corporation and Qiagen Inc. and previously served as a member of the boards of directors of Xerox Holdings Corporation, Covidien plc and MedQuist, Inc. He earned a bachelor’s degree in mechanical engineering from Worcester Polytechnic Institute and a Master of Management Science from the Massachusetts Institute of Technology’s Sloan School of Management.

About Baxter

Every day, millions of patients, caregivers and healthcare providers rely on Baxter’s leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.

Baxter is a registered trademark of Baxter International Inc.

Contacts

Media Contact
Stacey Eisen, (224) 948-5353
media@baxter.com

Investor Contact
Clare Trachtman, (224) 948-3020

Baxter International Inc.

NYSE:BAX

Release Versions

Contacts

Media Contact
Stacey Eisen, (224) 948-5353
media@baxter.com

Investor Contact
Clare Trachtman, (224) 948-3020

More News From Baxter International Inc.

Baxter Announces Cash Tender Offers

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced that it has commenced cash tender offers (each, an “Offer” and collectively, the “Offers”) for the maximum principal amount of validly tendered (and not validly withdrawn) notes set forth below (collectively, the “Notes”), such that the aggregate purchase price, not including accrued and unpaid interest, payable in respect of such Notes will not exceed $500 million. The terms and c...

Baxter Reports Second-Quarter 2026 Results

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2026. “Our second-quarter results exceeded expectations on both the top and bottom lines, driven by both operating performance and an additional benefit from a tariff refund that was not previously contemplated in our guidance,” said Andrew Hider, president and CEO. “While we’re encouraged by this steady progress and core operating momentum, we remain...

Baxter to Host Second-Quarter 2026 Financial Results Conference Call for Investors

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its second-quarter 2026 financial results on Thursday, July 30, 2026, at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://events.q4inc.com/attendee/167756971 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter’s website at www.bax...
Back to Newsroom